Retrolective Analysis of Brain Tumour Patients Adding Personalised Neoantigen Peptide Treatment To Their Standard Therapy in a Real-World Setting
- Neoantigen peptide immunization is well tolerated and induces durable T-cell responses in patients with difficult to treat brain tumours
- A diversified immune response to neoantigens significantly correlates with survival of immunized brain tumour patients
- Based on these experiences manufacturing workflows are optimized and clinical trials are designed